Alexandre J, Raymond E, Armand JP (1999) Rapamycin and CCI-779. Bull Cancer 86(10):808–811

Anisimov VN et al (2011) Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 10(24):4230–4236

Bitto A et al (2016) Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. elife 5:e16351

Boers-Doets CB et al (2013) Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol 9(12):1883–1892

Brattstrom C et al (1998) Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 65(9):1272–1274

Chen C, Liu Y, Zheng P (2009) mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal 2(98):ra75

Cohen E (2016) This pill could make your dog (and maybe you) live longer. (CNN)

Dai DF et al (2014) Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart. Aging Cell 13(3):529–539

Detweiler DK, Patterson DF (1965) The prevalence and types of cardiovascular disease in dogs. Ann N Y Acad Sci 127(1):481–516

Edinger AL, Linardic CM, Chiang GG, Thompson CB, Abraham RT (2003) Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res 63(23):8451–8460

Fischer KE et al (2015) Health effects of long-term rapamycin treatment: the impact on mouse health of enteric rapamycin treatment from four months of age throughout life. PLoS One 10(5):e0126644

Flynn JM et al (2013) Late-life rapamycin treatment reverses age-related heart dysfunction. Aging Cell 12(5):851–862

Gamaldo AA, Ferrucci L, Rifkind J, Longo DL, Zonderman AB (2013) Relationship between mean corpuscular volume and cognitive performance in older adults. J Am Geriatr Soc 61(1):84–89

Gilmore KM, Greer KA (2015) Why is the dog an ideal model for aging research? Exp Gerontol 71:14–20

Halloran J et al (2012) Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience 223:102–113

Harrison DE et al (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460(7253):392–395

Johnson SC, Martin GM, Rabinovitch PS, Kaeberlein M (2013) Preserving youth: does rapamycin deliver? Sci Transl Med 5(211):211fs240

Johnson SC, Sangesland M, Kaeberlein M, Rabinovitch PS (2015) Modulating mTOR in aging and health. Interdiscip Top Gerontol 40:107–127

Jones TC, Zook BC (1965) Aging changes in the vascular system of animals. Ann N Y Acad Sci 127(1):671–684

Kaeberlein M (2013) mTOR inhibition: from aging to autism and beyond. Scientifica (Cairo) 2013:849186

Kaeberlein M (2014) Rapamycin and aging: when, for how long, and how much? J Genet Genomics 41(9):459–463

Kaeberlein M (2015) The biology of aging: citizen scientists and their pets as a bridge between research on model organisms and human subjects. Vet Pathol

Kaeberlein M, Rabinovitch PS, Martin GM (2015) Healthy aging: the ultimate preventative medicine. Science 350(6265):1191–1193

Kaeberlein M, Creevy KE, Promislow DE (2016) The dog aging project: translational geroscience in companion animals. Mammalian genome: official journal of the International Mammalian Genome Society 27(7–8):279–288

Kealy RD et al (2002) Effects of diet restriction on life span and age-related changes in dogs. J Am Vet Med Assoc 220(9):1315–1320

Kennedy BK et al (2014) Geroscience: linking aging to chronic disease. Cell 159(4):709–713

Khan KH et al (2016) Hyperglycemia and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) inhibitors in phase I trials: incidence, predictive factors, and management. Oncologist 21(7):855–860

Lamming DW et al (2012) Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335(6076):1638–1643

Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274–293

Larson JC et al (2016) Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs. Am J Vet Res 77(1):65–71

Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013) The hallmarks of aging. Cell 153(6):1194–1217

Majumder S et al (2012) Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling. Aging Cell 11(2):326–335

Mannick JB et al (2014) mTOR inhibition improves immune function in the elderly. Sci Transl Med 6(268):268ra179

Miller RA et al (2011) Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 66(2):191–201

Neff MW, Rine J (2006) A fetching model organism. Cell 124(2):229–231

Neff F et al (2013) Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest 123(8):3272–3291

Paoloni MC et al (2010) Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs. PLoS One 5(6):e11013

Parikh JD, Hollingsworth KG, Wallace D, Blamire AM, MacGowan GA (2016) Normal age-related changes in left ventricular function: role of afterload and subendocardial dysfunction. Int J Cardiol 223:306–312

Pitt JN, Kaeberlein M (2015) Why is aging conserved and what can we do about it? PLoS Biol

Ross C et al (2015) Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus). Aging (Albany NY) 7(11):964–973

Sierra F, Kohanski R (2017) Geroscience and the trans-NIH Geroscience Interest Group, GSIG. Geroscience 39(1):1–5

Singh JP et al (1999) Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 83(6):897–902

Tardif S et al (2015) Testing efficacy of administration of the antiaging drug rapamycin in a nonhuman primate, the common marmoset. J Gerontol A Biol Sci Med Sci 70(5):577–587

Team RC (2016) R: a language and environment for statistical computing. R foundation for statistical Computing, Vienna

Templeton GH, Willerson JT, Platt MR, Weisfeldt M (1976) Contraction duration and diastolic stiffness in aged canine left ventricle. Recent Adv Stud Cardiac Struct Metab 11:169–173

Urfer SR et al (2017) Asymptomatic heart valve dysfunction in healthy middle-aged companion dogs and its implications for cardiac aging. Geroscience 39(1):43–50

Weinreich J et al (2011) Rapamycin-induced impaired wound healing is associated with compromised tissue lactate accumulation and extracellular matrix remodeling. Eur Surg Res 47(1):39–44

Wilkinson JE et al (2012) Rapamycin slows aging in mice. Aging Cell 11(4):675–682

Xie J, Wang X, Proud CG (2016) mTOR inhibitors in cancer therapy. F1000Res 5

Xu B & Daimon M (2016) Cardiac aging phenomenon and its clinical features by echocardiography. J Echocardiogr

Yi H et al (2014) Correction of glycogen storage disease type III with rapamycin in a canine model. J Mol Med 92(6):641–650